LACTOLOGY FOUNDATION

Tixocortol (ATC A07EA05) — Toxico-Lactological Monograph

ATC class and general pharmacology

Tixocortol, most commonly used clinically as its pivalate ester, is classified under ATC code A07EA05 within group A07E ("Intestinal anti-inflammatory agents"), subgroup A07EA ("Corticosteroids acting locally") (WHO ATC/DDD Index; DrugCentral). This code applies specifically to rectal/enema formulations used in distal ulcerative colitis; the same molecule carries a separate ATC code (R01AD07) when formulated as a nasal spray for allergic and inflammatory rhinitis, and it is additionally marketed as oropharyngeal lozenges for pharyngitis (DrugBank; PubChem).pubchem.ncbi.nlm.nih+3

Chemically, tixocortol is a 21-thiol derivative of hydrocortisone, classified as a "Class A" corticosteroid together with hydrocortisone and related short-chain esters. Its therapeutic form, tixocortol pivalate, binds the glucocorticoid receptor and inhibits prostaglandin synthesis and pro-inflammatory cytokine expression in a manner mechanistically similar to other corticosteroids, but its defining pharmacological feature is an exceptionally pronounced dissociation between local (topical) anti-inflammatory potency and systemic glucocorticoid activity. This dissociation arises from a distinctive pharmacokinetic profile: oral bioavailability of only 10–20%, a volume of distribution roughly ten times greater than cortisol (approximately 21.7 L/kg in animal models), and extremely rapid biotransformation — beginning within red blood cells and continuing via first-pass hepatic metabolism — into sulfo- and glucurono-conjugated metabolites that have no residual affinity for the glucocorticoid receptor (BenchChem technical guide; DrugBank). Unchanged parent drug is essentially undetectable in urine even after very high oral doses, confirming near-complete presystemic inactivation.pubmed.ncbi.nlm.nih+4

Toxicological profile

Tixocortol pivalate is notable among corticosteroids acting locally for its almost complete lack of measurable systemic glucocorticoid toxicity. Controlled human studies administering tixocortol pivalate orally, intrarectally, and intranasally found no significant changes in plasma cortisol, leukocyte differential counts, blood glucose, or urinary sodium/potassium excretion — parameters that were altered by comparator corticosteroids such as dexamethasone and betamethasone in the same study. Regulatory pharmacological data further indicate that administration of up to 130 times the standard therapeutic daily dose in humans produced no detectable systemic glucocorticoid effect, and animal comparisons show tixocortol pivalate to be 60–300 times less systemically active than hydrocortisone acetate by oral or subcutaneous routes despite comparable local anti-inflammatory efficacy (ANSM Summary of Product Characteristics; Pharmacological study, 1980).pubmed.ncbi.nlm.nih+2

The principal toxicological concern associated with tixocortol is therefore not systemic corticosteroid toxicity (adrenal suppression, Cushingoid effects, metabolic derangement) but immunologic sensitization. Tixocortol pivalate is a well-characterized contact allergen and is used internationally as the standard diagnostic marker (e.g., in the TRUE Test allergen panel) for screening delayed-type hypersensitivity (Type IV) contact allergy to Class A corticosteroids (Biomedicus clinical review; PharmaCompass). In sensitized individuals, cutaneous or mucosal exposure can provoke allergic contact dermatitis, with potential cross-reactivity to other Class A corticosteroids (hydrocortisone, prednisolone, cortisone). Local nasal, pharyngeal, or rectal mucosal irritation may also occur with the respective formulations. No significant hepatic, renal, endocrine, or hematologic organ toxicity has been documented, consistent with the drug's rapid inactivation pathway.biomedicus+1

Lactation pharmacology and infant exposure

No dedicated pharmacokinetic study or LactMed monograph documenting the excretion of tixocortol or tixocortol pivalate into human milk has been identified in the available literature. Direct clinical lactation data for this specific molecule are therefore absent, and no case reports of infant exposure via breastfeeding have been published.

In the absence of direct data, risk assessment must rely on pharmacological plausibility derived from tixocortol's established systemic pharmacokinetics. Given its low oral bioavailability (10–20%), large volume of distribution, and — most importantly — its rapid and near-complete presystemic conversion into pharmacologically inactive metabolites lacking glucocorticoid receptor affinity, the fraction of active parent compound available for transfer into the systemic circulation (and by extension into breast milk) is expected to be minimal, considerably lower than for systemically absorbed corticosteroids such as betamethasone or prednisolone (DrugBank; BenchChem). This places tixocortol pharmacokinetically closer to genuinely low-systemic-bioavailability topical/locally acting corticosteroids, which general lactation guidance considers to produce "very small or negligible systemic concentrations in the mother, leading to negligible concentrations in the breast milk".drugbank+2

This inference should nonetheless be applied cautiously, since it is extrapolated from pharmacokinetic principles rather than confirmed by direct milk-level measurements or infant outcome data specific to tixocortol.

Lactological safety assessment and clinical recommendations

Based on tixocortol's pharmacokinetic profile — extensive presystemic inactivation, low active systemic exposure, and an established safety record showing absence of systemic glucocorticoid effects even at markedly supratherapeutic doses — tixocortol (rectal, nasal, or oropharyngeal formulations, ATC A07EA05 / R01AD07) can reasonably be regarded as presenting a low theoretical risk of clinically relevant infant exposure via breast milk, comparable in principle to other locally acting corticosteroids considered compatible with breastfeeding. However, the complete absence of dedicated human lactation studies for this specific agent warrants a precautionary, individualized approach rather than an unqualified assurance of safety.

Clinical recommendations:

• General compatibility with caution: In the absence of direct lactation data, tixocortol may be used during breastfeeding when clinically indicated, applying the standard precautionary principle of using the lowest effective dose for the shortest necessary duration.sps.nhs
• Avoid breast/nipple contact: For any topical or mucosal formulation, avoid direct contact between treated mucosal or skin surfaces and the infant's mouth or skin; wash hands thoroughly before breastfeeding or infant handling.
• Monitor for maternal contact sensitization: Given tixocortol's recognized role as a corticosteroid contact allergen, monitor for signs of allergic contact dermatitis at the application site; a positive history of tixocortol pivalate patch-test allergy should prompt caution with cross-reactive Class A corticosteroids considered as alternatives during lactation.
• No routine interruption of breastfeeding required: Standard therapeutic use of tixocortol (nasal, rectal, or oropharyngeal) does not warrant withholding breastfeeding or discarding milk, given the pharmacologically low expected systemic and milk exposure.
• Infant monitoring: Routine infant monitoring for adverse effects is not specifically indicated based on current pharmacological reasoning, but any unexpected infant symptoms during maternal use should prompt clinical evaluation given the lack of confirmatory human lactation data.
• Documentation gap awareness: Clinicians and lactation consultants should recognize that safety conclusions for tixocortol during breastfeeding are inferential (pharmacokinetics-based) rather than derived from direct milk-transfer studies, and should communicate this evidence limitation transparently to breastfeeding patients.